NeuroKaire (formerly Genetika+)

NeuroKaire is a precision medicine company founded in 2018 in Israel, focused on transforming psychiatry and neurology through treatment optimization and drug development. The company operates from offices in Kearny, New Jersey, and Tel Aviv-Yafo, and is led by a women-driven team. NeuroKaire aims to enhance mental health care with evidence-based technology, initially targeting major depression.

The company utilizes a proprietary "brain-in-a-dish" screening platform that converts patient blood cells into neurons. This innovative technology allows for personalized predictions of medication responses, helping healthcare providers identify the most effective antidepressant therapies for individual patients. NeuroKaire's first product, BrightKaire, is a blood-based clinical laboratory test that predicts medication response with 79.3% accuracy. The company is expanding its reach by partnering with healthcare networks and mental health clinics across the United States.

NeuroKaire operates a dual business model that includes clinical lab testing and pharmaceutical partnerships. The company collaborates with mental health clinics for patient testing and works with pharmaceutical companies to enhance drug development success rates.